Sugi Predict

Sugi Predict / Compounds / SCHEMBL743357

SCHEMBL743357

SCHEMBL743357

CC(C)(C)OC(=O)N[C@H](Cc1ccccc1)[C@@H](O)C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KLK5 Q9Y337 3/20 0.61
▸ ATM Q13315 1/20 0.57
▸ ACE P12821 1/20 0.56
▸ CTSS P25774 3/20 0.55
▸ CTSK P43235 2/20 0.55
▸ CTSL P07711 1/20 0.55
▸ CTSB P07858 1/20 0.55
▸ PPARA Q07869 2/20 0.51
▸ PPARG P37231 1/20 0.51
▸ PSEN1 P49768 3/20 0.51
▸ PSEN2 P49810 3/20 0.51
▸ APH1B Q8WW43 3/20 0.51
▸ NCSTN Q92542 3/20 0.51
▸ APH1A Q96BI3 3/20 0.51
▸ PSENEN Q9NZ42 3/20 0.51
▸ APP P05067 4/20 0.50
▸ AKT1 P31749 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3447452 1.00 KLK5 (0.61) KLK5ATMACECTSSCTSK
SCHEMBL288838 1.00 KLK5 (0.61) KLK5ATMACECTSSCTSK
SCHEMBL5650822 1.00 KLK5 (0.61) KLK5ATMACECTSSCTSK
SCHEMBL3837973 1.00 KLK5 (0.61) KLK5ATMACECTSSCTSK
SCHEMBL15775826 1.00 KLK5 (0.61) KLK5ATMACECTSSCTSK
SCHEMBL825622 1.00 KLK5 (0.61) KLK5ATMACECTSSCTSK
SCHEMBL7356486 1.00 KLK5 (0.61) KLK5ATMACECTSSCTSK
SCHEMBL4275825 0.92 KLK5 (0.58) KLK5ATMACECTSSCTSK
SCHEMBL4955577 0.92 KLK5 (0.58) KLK5ATMACECTSSCTSK
SCHEMBL6343884 0.90 KLK5 (0.60) KLK5ATMACECTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4702005-A1 CNDP2 MODULATORS AND METHODS FOR THEIR USE Metabolon Inc. (US) 2026-03-04 — — EP disclosed
EP-4622996-A1 CONTROL OF NANOCAGE SELF-ASSEMBLY King's College London (GB) 2025-10-01 — — EP disclosed
US-20250206802-A1 MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-06-26 — — US disclosed
US-20250120927-A1 CNDP2 MODULATORS AND METHODS FOR THEIR USE METABOLON INC. 2025-04-17 — — US disclosed
WO-2024227056-A1 CNDP2 MODULATORS AND METHODS FOR THEIR USE METABOLON INC. (US) 2024-10-31 — — WO disclosed
WO-2024110757-A1 CONTROL OF NANOCAGE SELF-ASSEMBLY KING'S COLLEGE LONDON (GB) 2024-05-30 — — WO disclosed
US-20240117006-A1 MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2024-04-11 — — US disclosed
US-20220195017-A1 PATHOGEN BINDING METHODS AND COMPOSITIONS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2022-06-23 — — US disclosed
US-11021709-B2 Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2021-06-01 — — US disclosed
US-20200362350-A1 LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2020-11-19 — — US disclosed
US-20130064895-A1 Amphiphilic Peptides and Peptide Particles PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-03-14 — — US disclosed
WO-2013028843-A1 PEPTIDE NANOPARTICLES AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-02-28 — — WO disclosed
WO-2012177986-A2 CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS VYOME BIOSCIENCES (IN) 2012-12-27 — — WO disclosed
US-20120308587-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2012-12-06 — — US disclosed
US-20120308588-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2012-12-06 — — US disclosed
US-20120309724-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2012-12-06 — — US disclosed
US-20120309724-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2012-12-06 — — US disclosed
WO-2012166390-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2012-12-06 — — WO disclosed
US-8138168-B1 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-20 — — US disclosed
WO-2011159917-A2 GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2011-12-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240117006-A1 MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF ITGA2B, ITGB1, ITGA1 KLK5 2838/4885ATM 3383/4885ACE 3963/4885
US-20120309724-A1 NEPRILYSIN INHIBITORS MME, REN, ACE KLK5 71/4885ATM 4839/4885ACE 3/4885
US-20120308588-A1 NEPRILYSIN INHIBITORS MME, REN, ACE KLK5 93/4885ATM 4840/4885ACE 3/4885
US-20120308587-A1 NEPRILYSIN INHIBITORS MME, REN, ACE KLK5 66/4885ATM 4846/4885ACE 3/4885
US-20250120927-A1 CNDP2 MODULATORS AND METHODS FOR THEIR USE CNDP2, DPP7, DPEP1 KLK5 1947/4885ATM 3585/4885ACE 108/4885
US-20250206802-A1 MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF ITGA2B, ITGB1, ITGA1 KLK5 2838/4885ATM 3383/4885ACE 3963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.